New research shows that the drug Tamoxifen can greatly reduce the risk of a second breast cancer diagnosis in women who carry the BRCA1 or BRCA2 genes. Women with the “breast cancer genes” are not often offered Tamoxifen as part of a treatment plan. These findings could change that.
Investigators at the Peter MacCallum Cancer Centre in Australia studied thousands of women with the BRCA1 and BRCA2 genes over a span of 8 years. During that time, women with the BRCA1 mutation were 63 percent less likely to develop a second cancer after taking Tamoxifen and women with the BRCA2 gene had a 67 percent lower risk with the drug.
To read more on the study, click here.